title: Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
abstract: The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon-like peptide-1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called "incretin defect" in patients with T2DM.
authors.affiliation: Grunberger Diabetes Institute, Bloomfield Hills, Michigan 48302, USA. grunberger@gdi-pc.com
authors.forename: George
authors.initials: G
authors.lastname: Grunberger
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D000077270:Exenatide; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000627:therapeutic use*; D015394:Molecular Structure; D010455:Peptides / Q000627:therapeutic use; D011719:Pyrazines / Q000737:chemistry / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000737:chemistry / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D054795:Incretins; D010455:Peptides; D011719:Pyrazines; D018027:Receptors, Glucagon; D014230:Triazoles; D014688:Venoms; D000077270:Exenatide; D000068900:Sitagliptin Phosphate
keywords: antidiabetic drugs; dipeptidyl peptidase 4 inhibitors; glucagon-like peptide-1 receptor agonists; incretin analogs; type 2 diabetes therapy; 降糖药物，二肽基肽酶4抑制剂，胰高血糖素样肽-1受体激动剂，肠促胰岛素类似物，2型糖尿病治疗